BCM
EVH icon

BlueCrest Capital Management’s Evolent Health EVH Stock Holding History

BlueCrest Capital Management’s Portfolio EVH Stock Details EVH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$242K Hold
106,300
– – 0.01% 217
2025
Q4 		$425K Buy
+106,300
New +$591K 0.01% 153

Other funds holding EVH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RF
Rubicon Founders Nashville, Tennessee $138M AUM 61.96% 1-Year Est. Return
EC
Engaged Capital Newport Beach, California $303M AUM 2.09% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlueCrest Capital Management's EVH Position: Q4 2017 in Review

BlueCrest Capital Management sold out of Evolent Health (EVH) in Q4 2017, closing a stake of 57,700 shares — an estimated $1.03M sold.

BlueCrest Capital Management first reported a position in EVH in Q1 2017 and held it in 3 quarters. The position peaked at $2.26M in Q1 2017. 156 funds tracked by Wall St. Rank hold EVH as of Q4 2017.

  • BlueCrest Capital Management reported no remaining Evolent Health position as of Q4 2017 after selling out during the quarter.
  • BlueCrest Capital Management sold 57,700 Evolent Health shares in Q4 2017, an estimated $1.03M.
  • BlueCrest Capital Management first reported a position in Evolent Health in Q1 2017 and held it in 3 quarters.
  • BlueCrest Capital Management's Evolent Health position peaked at $2.26M in Q1 2017.
  • 156 funds tracked by Wall St. Rank held Evolent Health as of Q4 2017.

Based on BlueCrest Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.